Microbio is pleased to announce a new distributor agreement with Mobius Life Science, a well-established provider of innovative diagnostic solutions in Brazil. This partnership marks a significant step in expanding access to Microbio’s InfectID™-BSI test in the Latin American market.
Sepsis remains a major healthcare challenge in Brazil, with a mortality rate of at least 25% among the 800,000 plus cases recorded annually. Rapid and accurate pathogen detection is critical in improving patient outcomes, and InfectID™-BSI offers a powerful solution by enabling targeted treatment within hours, rather than days.
InfectID™-BSI is a groundbreaking molecular diagnostic test that identifies 26 sepsis-associated pathogens, enabling clinicians to administer targeted treatment in three hours. The assay works by targeting the pathogen’s DNA ‘fingerprint.’ Utilizing melt curve technology, InfectID™-BSI rapidly identifies sepsis-causing pathogens directly from blood samples. Without the need for enrichment or culture, this CE-marked product offers a powerful tool to improve patient outcomes through quicker and more accurate treatment, addressing sepsis, which contributes to millions of deaths globally each year.
Microbio is committed to improving patient outcomes through advanced diagnostic technologies, and this partnership marks a significant step in expanding access to InfectID™-BSI across Brazil.
Mobius Life Science specializes in providing cutting-edge diagnostic and life science solutions to laboratories and healthcare facilities in Brazil. Through this partnership, the company will leverage its industry expertise to introduce Microbio’s innovative technology to a broader audience, supporting improved clinical decision-making and patient care.